-
Mashup Score: 1ARCADIA: Apixaban No Help for ESUS Patients With Atrial Cardiopathy - 11 month(s) ago
The idea that atrial cardiopathy may identify a group that would benefit from anticoagulation isn’t dead, one expert says.
Source: TCTMD.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 2Wolters Kluwer Health - 12 month(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Latest Headlines, NeurologyTweet-
Physicians often hesitate to prescribe oral anticoagulants to people with #AtrialFibrillation and #dementia, but a new analysis shows #apixaban was effective and safe compared to older oral anticoagulants: https://t.co/c7M2Vm9kBW #neurotwitter @AANMember @costantinoiade1 https://t.co/6KDmwFrKYd
-
-
Mashup Score: 0Wolters Kluwer Health - 1 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Emergency Medicine, Latest HeadlinesTweet-
A #patient on #apixaban suffered a fall. #CT imaging revealed a #subduralhematoma & developing uncal #herniation. @thame says an #algorithm created by Taylor Martin, MD, can help with the reversal of #anticoagulation for intracranial #hemorrhage. #FOAMed https://t.co/90ON0wBUOb https://t.co/VJzPNgwrXl
-
-
Mashup Score: 1No differences in bleeding, thromboembolic events with DOACs vs. warfarin after surgery - 1 year(s) ago
Patients who received apixaban or rivaroxaban after cardiac surgery were no more likely to experience major bleeding or thromboembolic events compared with patients who received warfarin after surgery, data from a single-center study show.“Landmark studies of the major direct oral anticoagulant agents were not designed to study outcomes in cardiac surgery patients,” Alan J. Rozycki,
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Patients who received #apixaban or #rivaroxaban after cardiac surgery were no more likely to experience major bleeding or thromboembolic events compared with patients who received warfarin after surgery @OSUWexMed @JCardSurg #cardiotwitter https://t.co/1T2BwzvtFR
-
-
Mashup Score: 0NEJM Journal Watch: Summaries of and commentary on original medical and scientific articles from key medical journals - 1 year(s) ago
NEJM Journal Watch reviews over 250 scientific and medical journals to present important clinical research findings and insightful commentary
Source: www.jwatch.orgCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
How does the efficacy and safety of #apixaban compare with warfarin for patients with end-stage renal disease and venous thromboembolism? https://t.co/niu9jWX39i #VTE @DresslerDD https://t.co/OeX9OZ4rpt
-
-
Mashup Score: 6
Background: Current guidelines recommend using direct oral anticoagulants (DOACs) over warfarin in patients with atrial fibrillation (AF), but head-to-head trial data do not exist to guide the choice of DOAC. Objective: To do a large-scale comparison between all DOACs (apixaban, dabigatran, edoxaban, and rivaroxaban) in routine clinical practice. Design: Multinational population-based cohort…
Source: Annals of Internal MedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
A study of persons with #Afib found that compared w/ all DOACs, #apixaban was associated with lower rates of GI bleeding, but similar rates of stroke, ICH, and mortality: https://t.co/iMGbh5f33A @Ian_HKU @wallis_lau @School_Pharmacy https://t.co/6oM5LIvrU5
-
-
Mashup Score: 0Annals of Internal Medicine: Latest - 2 year(s) ago
Original ResearchIdeas and OpinionsACP Journal ClubWeb ExclusivesOriginal ResearchPosition PapersIdeas and OpinionsEditorialsLettersSafety and Immunogenicity of Intradermal Fractional Dose Administration of the mRNA-1273 Vaccine: A Proof-of-Concept StudyWeb ExclusivesOriginal ResearchReviewsLettersPrevalence and Correlates of Patient Rationing of Insulin in the United States: A National SurveyAd…
Source: Annals of Internal MedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
The latest from Annals of Internal Medicine is online now. Explore new research on #apixaban, CFTR function, and more: https://t.co/hqDoN4dom3 https://t.co/OnldKezueh
-
-
Mashup Score: 2
Background: Although apixaban and rivaroxaban are commonly used in patients with atrial fibrillation (AF) and valvular heart disease (VHD), there is limited evidence comparing the 2 drugs in these patients. Objective: To emulate a target trial of effectiveness and safety of apixaban and rivaroxaban in patients with AF and VHD. Design: New-user, active comparator, cohort study design. Setting:…
Source: Annals of Internal MedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
New from @PennMedicine: Comparison of blood thinners finds important differences. #apixaban associated with lower rate of ischemic stroke, embolism, intracranial/GI bleeding compared with #rivaroxaban in patients with #afib and valvular #heartdisease: https://t.co/y7rrlD0jb9 https://t.co/MMQpbQW4oQ
-
-
Mashup Score: 1
Compared with rivaroxaban, patients who received apixaban had a 43% reduced risk of stroke or embolism.
Source: www.mdedge.comCategories: Hem/Oncs, Latest HeadlinesTweet-
#Apixaban outmatches #Rivaroxaban in patients with #AFib and valvular heart disease👇 https://t.co/mFxC4Lz2X3 @MDedgeHemOnc @PennMDForum #VHD #Penn https://t.co/TNzpbSxleU
-
-
Mashup Score: 8Artivion Follows Recommendation to Stop PROACT Xa Clinical Trial - 2 year(s) ago
/PRNewswire/ — Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has stopped the…
Source: www.prnewswire.comCategories: Expert Picks, Latest HeadlinesTweet-
PROACT Xa a randomized trial, stopped based on recommendation of independent Data and Safety Monitoring Board (DSMB) of the trial due to lack of evidence supporting non-inferiority of #apixaban to warfarin for valve thrombosis and thromboembolism. https://t.co/8JGDQUHcYq
-
#ARCADIA trial shows #Apixaban does not help for #ESUS Patients With Atrial #Cardiopathy @TCTMD @mmamas1973 @mirvatalasnag @ShelleyWood2 @vass_vassiliou @hvanspall https://t.co/sFKGFaEZSj